Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Palisade Bio (PALI) Equity Average (2016 - 2025)

Palisade Bio (PALI) has disclosed Equity Average for 15 consecutive years, with $2.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average fell 64.78% to $2.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.9 million, a 64.78% decrease, with the full-year FY2024 number at $9.4 million, down 20.96% from a year prior.
  • Equity Average was $2.9 million for Q3 2025 at Palisade Bio, down from $4.0 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $14.9 million in Q3 2023 to a low of -$18.3 million in Q1 2021.
  • A 5-year average of $5.5 million and a median of $7.7 million in 2024 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: plummeted 97.54% in 2021, then soared 401.25% in 2022.
  • Palisade Bio's Equity Average stood at -$2.8 million in 2021, then surged by 550.92% to $12.5 million in 2022, then grew by 1.95% to $12.7 million in 2023, then tumbled by 44.48% to $7.0 million in 2024, then plummeted by 58.64% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Equity Average are $2.9 million (Q3 2025), $4.0 million (Q2 2025), and $6.4 million (Q1 2025).